Hi Bavarian &
@tassy Devil,
Merck (MSD) are certainly not out of the picture & this deal with Seagen we’ve all been reading the last few weeks. If anything, it helps to give perspective & they will still be at the mercy of anti-trust laws etc before this Merger can be passed.
Licencing deals are another story. Hopefully Keytruda & Check-Vacc, Vaxinia & Keytruda trials are successful.
Don’t discount anything, so much going on right now. That’s the way I see it.
[/QUOTE
OVF, This Seagen deal is really exciting. And it clearly highlights how undervalued IMU is even at this stage.
The links posted here are well worth reading yo better understand how well positioned IMU is. LC has done a brilliant job. SEAGEN has developed a technology for treating solid tumors. Merck wants to pair Keytruda with Seagen’s drug to enhance the outcomes for patients . Keytruda only works fo a fraction of the possible patients. Merck are hoping to change that with this deal.
I won’t rewrite these articles here but, it’s clear that our technologies are far superior in may aspects. There is no mention of toxicity in these links, nor any mention of immune memory to produce more antibodies should the cancer return . Nor do they have the ability to hunt down metastic distal tumours.
Valuations of companies are often use discounted cash flows, but that’s clearly impossible for earlier stage drug companies like ours . It’s better to use recent sales of compyanf technologies in the same or similar space, as done in real estate.. It impossible to know what cash flows could come to IMU with all its permeations into the future.. There were studies of a similar nature trying to ascertain if the box office takings for movies could be predicted. The research showed it was impossible to predict. The same principles would equally true for drugs.
A comparison valuation between companies such as IMU and Seagen woukd be a much more reliable way to value drug companies. Particularly for us because our buyer will be a Big Pharma, not cancer patients,
It’s clear to me that IMU is holding much better assets than Seagen. Their technology does not come with many of the exciting benefits that ours do. This might sound crazy from a shareprice of .23 cents, but this deal certainly makes it clear that IMU won’t be selling for any less than US$40bn, and probably much more.
https://www.biopharmadive.com/news/seagen-tukysa-colorectal-cancer-results-esmo/626579/
https://www.biopharmadive.com/news/seattle-genetics-merck-antibody-cancer-drug-deal/585159/
(20min delay)